Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Reviva Pharmaceuticals Schizophrenia Drug Demonstrates Strong Efficacy On Heels Of Bristol Myers, FDA Approval: Analyst
Last month, Reviva Pharmaceuticals released new vocal biomarker data from the Phase 3 RECOVER trial of brilaroxazine in schizophrenia.Last week, the FDA approved Bristol Myers Squibb & Co's (NYSE:BMY) Cobenfy (xanomeline and trospium chloride, KarXT), an oral medication for schizophrenia in adults.
上周，FDA批准了Bristol Myers Squibb（纽交所：BMY）的Cobenfy（xanomeline和trospium chloride，KarXT），这是一种针对成年人精神分裂症的口服药物。
Analysts at investment bank EF Hutton says, "This bodes well for Reviva's Brilaroxazine, a multi-receptor-targeting antipsychotic that primarily focuses on serotonin (5-HT2A, 5-HT7), dopamine (D2, D3), and adrenergic receptors."
投资银行EF Hutton的分析师表示：“这对Reviva的Brilaroxazine是个好兆头，这是一种以5-羟色胺（5-HT2A、5-HT7）、多巴胺（D2、D3）和肾上腺素受体为主要靶点的多受体靶向抗精神病药物。”
Reviva Pharmaceuticals Holdings, Inc.'s (NASDAQ:RVPH) pipeline currently includes two drug candidates, brilaroxazine (RP5063) and RP1208.
reviva pharmaceuticals控股公司（纳斯达克：RVPH）目前的产品线包括两种药物候选品，brilaroxazine（RP5063）和RP1208。
Last month, Reviva Pharmaceuticals released new vocal biomarker data from the Phase 3 RECOVER trial of brilaroxazine in schizophrenia.
上个月，Reviva Pharmaceuticals发布了brilaroxazine在精神分裂症RECOVER第三阶段试验中的新声音生物标志数据。
Brilaroxazine demonstrated a strong efficacy for negative symptoms and other key symptoms of schizophrenia, such as total and positive symptoms, disorganization, and social functioning in the pivotal phase 3 RECOVER trial in schizophrenia.
在重要的第三阶段精神分裂症RECOVER试验中，brilaroxazine表现出对于负性症状和其他关键症状（如总体和阳性症状、紊乱和社会功能）的强效性。
The analyst notes that while Cobenfy primarily acts as a dopamine D2 partial agonist with limited serotonin receptor involvement, Brilaroxazine targets a broader range of receptors. This expanded activity could have a wider therapeutic impact, especially on cognitive symptoms.
分析师指出，尽管Cobenfy主要作为多巴胺D2部分激动剂，涉及到的5-羟色胺受体有限，而Brilaroxazine则针对更广泛的受体。这种扩增活性可能会产生更广泛的治疗影响，尤其是在认知症状方面。
The analyst further highlights that both Cobenfy and Brilaroxazine are effective in addressing the positive and negative symptoms of schizophrenia. However, Brilaroxazine's action on the 5-HT7 receptor, which plays a crucial role in cognition, may offer added benefits in cognitive enhancement.
分析师进一步强调，Cobenfy和Brilaroxazine都有效地针对精神分裂症的阳性和负性症状。不过，Brilaroxazine对5-HT7受体的作用，这在认知中扮演重要角色，可能提供认知增强的附加好处。
In terms of side effects, Cobenfy presents a more typical profile for second-generation antipsychotics, including risks of weight gain and metabolic issues. Brilaroxazine, on the other hand, is being developed to mitigate these metabolic concerns and minimize movement-related side effects.
就副作用而言，Cobenfy呈现出更典型的第二代抗精神病药物特征，包括体重增加和代谢问题的风险。另一方面，Brilaroxazine正在开发以减轻这些代谢问题并将运动相关副作用最小化。
The analyst concludes that Cobenfy and Brilaroxazine take distinct paths in treating schizophrenia. Both therapies offer value in the treatment landscape, but Brilaroxazine's potential cognitive advantages and improved metabolic profile could give it an edge upon approval.
分析师得出结论，Cobenfy和Brilaroxazine在治疗精神分裂症方面采取不同的路径。这两种疗法在治疗领域中都提供了价值，但Brilaroxazine潜在的认知优势和改善的代谢特性可能在获批后使其具备优势。
Price Action: Reviva Pharmaceuticals stock is down 4.8% at $1.19 at last check Monday.
股价走势：reviva pharmaceuticals股票最新报价下跌4.8%，报1.19美元，截至上周一最后查看。
Read next:
阅读下一篇：
- What's Going On With Trump Media & Technology Stock On Monday?
- 周一特朗普媒体科技股票发生了什么？
热门市场机会
热门讨论
热门讨论
